ReviewFrontiers in pharmacology2018
The Role of Gut Microbiota in Atherosclerosis and Hypertension.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05795946 (Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.), which is not on this map. Cited by 115 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of a Whole Food Based Nutritional Formulation on Trimethylamine N-oxide and Cardiometabolic Endpoints in Healthy Adults.
Who cites it
115 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The association between the gut microbiota metabolite trimethylamine N-oxide and heart failure.Frontiers in microbiology · 2024Pooled it
- Effects of Berries, Phytochemicals, and Probiotics on Atherosclerosis through Gut Microbiota Modification: A Meta-Analysis of Animal Studies.International journal of molecular sciences · 2023Pooled it
- Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value.Frontiers in cardiovascular medicine · 2022Pooled it
- Gut-derived bacterial extracellular vesicles: the microbial dark matter contributing to host inflammation and cardiometabolic disease.Gut microbes · 2026Review
- Gut microbiota and fecal 2-methylbutyric acid in coronary heart disease: a cross-sectional study.Scientific reports · 2026Article
- Gut microbial community structure, metabolic signature, and resistome in dyslipidemia: implications for cardiovascular disease management.Microbiology spectrum · 2026Article
- Multi-Omics Mechanisms of Trimethylamine Oxide and Cardiovascular Disease: A Review.Reviews in cardiovascular medicine · 2026Review
- Study on the Mechanism ofBiomolecules · 2026Article
- High Salt Intake and Atherosclerosis Progression-Not Only via Blood Pressure: A Narrative Review.Nutrients · 2025Review
- The mediating role of inflammatory factors in the association between dietary index for gut microbiota and hypertension.Scientific reports · 2025Article
- Paeoniflorin improves atherosclerosis by regulating the gut microbiota and fecal metabolites.mSystems · 2025Article
- Gut Microbiota-Derived Metabolites in Atherosclerosis: Pathways, Biomarkers, and Targets.International journal of molecular sciences · 2025Review
- From gut microbial ecology to lipid homeostasis: Decoding the role of gut microbiota in dyslipidemia pathogenesis and intervention.World journal of gastroenterology · 2025Review
- Tanshinone regulated gut microbiota and TMAO to improve high-fat diet induced atherosclerosis in APOEBMC microbiology · 2025Article
- Environmental Toxins and Oxidative Stress: The Link to Cardiovascular Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Review
- Integrated Microbiome and Metabolome Analysis Reveals Correlations Between Gut Microbiota Components and Metabolic Profiles in Mice With Mitoxantrone-Induced Cardiotoxicity.Drug design, development and therapy · 2025Article
- The Gut Health Revolution: Herbs and Dietary Phytochemicals in Balancing Gut Microbiota for Optimal Human Health.Current pharmaceutical biotechnology · 2025Review
- The role of intestinal microbiota and its metabolites in the occurrence and intervention of obesity.Frontiers in microbiology · 2025Review
- Essential Hypertension as an Independent Risk Factor for Erosive Esophagitis: Insights From a Single-Center Retrospective Cohort Analysis.Journal of inflammation research · 2025Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, accumulating evidence has indicated the importance of gut microbiota in maintaining human health. Gut dysbiosis is associated with the pathogenesis of a number of metabolic diseases including obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and cardiovascular diseases (CVDs). Indeed, CVD has become the leading cause of death worldwide, especially in developed countries. In this review, we mainly discuss the gut microbiota-involved mechanisms of CVD focusing on atherosclerosis and hypertension, two major risk factors for serious CVD. Then, we briefly discuss the prospects of gut microbiota-targeted therapeutic strategies for the treatment of CVD in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.